Our Pipeline

Our multivalent, TNF superfamily candidates are precisely engineered to drive optimized receptor clustering.

The Candidates

Phase 1
Phase 2
Phase 3


Our Tetravalent DR5 Agonist


INBRX-109 is a precisely engineered tetravalent sdAb-based therapeutic candidate that agonizes DR5 to induce tumor selective programmed cell death.

Learn more Phase 1 Trial
Inbrx 109


Our Hexavalent OX40 Agonist


INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40 currently being evaluated in patients with locally advanced or metastatic solid tumors. Signaling through OX40 provides co-stimulation that promotes T-cell expansion, enhanced effector function and memory cell formation, and prevents activation-induced cell death.

Learn more clinicaltrials.gov
Inbrx 106